Health Catalyst, Inc. (NASDAQ:HCAT) Receives $4.36 Consensus Price Target from Analysts

Health Catalyst, Inc. (NASDAQ:HCAT) has been assigned an average rating of “Hold” from the fourteen research firms that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, eight have issued a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $4.3636.

Several research analysts recently issued reports on HCAT shares. Cantor Fitzgerald reissued a “neutral” rating and set a $4.00 target price on shares of Health Catalyst in a report on Tuesday, October 7th. Summit Redstone set a $5.00 price objective on Health Catalyst in a research note on Friday, August 29th. UBS Group reissued an “outperform” rating on shares of Health Catalyst in a report on Tuesday, November 11th. Citigroup dropped their target price on Health Catalyst from $3.50 to $3.25 and set a “neutral” rating on the stock in a report on Tuesday, November 11th. Finally, Piper Sandler cut Health Catalyst from an “overweight” rating to a “neutral” rating and reduced their price target for the company from $8.00 to $4.00 in a research report on Wednesday, August 27th.

Health Catalyst Stock Performance

Shares of HCAT stock opened at $2.60 on Friday. The business has a fifty day moving average of $2.84 and a 200 day moving average of $3.31. Health Catalyst has a 1 year low of $2.02 and a 1 year high of $8.74. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.88 and a quick ratio of 1.88. The firm has a market capitalization of $183.90 million, a price-to-earnings ratio of -1.64 and a beta of 1.72.

Health Catalyst (NASDAQ:HCAT) last announced its quarterly earnings data on Monday, November 10th. The company reported $0.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.05 by $0.01. Health Catalyst had a negative return on equity of 6.67% and a negative net margin of 34.05%.The business had revenue of $76.32 million for the quarter, compared to analyst estimates of $75.05 million. As a group, research analysts expect that Health Catalyst will post -0.33 earnings per share for the current year.

Hedge Funds Weigh In On Health Catalyst

Large investors have recently made changes to their positions in the company. Numerai GP LLC acquired a new stake in Health Catalyst during the third quarter valued at $351,000. Millennium Management LLC boosted its stake in shares of Health Catalyst by 2,513.3% during the 3rd quarter. Millennium Management LLC now owns 1,589,536 shares of the company’s stock worth $4,530,000 after acquiring an additional 1,528,710 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Health Catalyst during the 3rd quarter worth about $90,000. Moore Capital Management LP grew its position in shares of Health Catalyst by 130.8% during the 3rd quarter. Moore Capital Management LP now owns 398,857 shares of the company’s stock valued at $1,137,000 after acquiring an additional 226,023 shares during the period. Finally, First Light Asset Management LLC increased its stake in shares of Health Catalyst by 9.9% in the 3rd quarter. First Light Asset Management LLC now owns 13,436,220 shares of the company’s stock valued at $38,293,000 after purchasing an additional 1,206,039 shares in the last quarter. 85.00% of the stock is currently owned by institutional investors and hedge funds.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.